

**CERTIFICATE OF MAILING**

hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop AF; Commissioner for Patents, Washington, DC 20231 on December 20, 2006.

Marlene Troxle
Marlene Troxle

PATENT

8085

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Hirotaka Uchlyama et al : Paper No.:
Serial No.: 09/855,337 : Group Art Unit: 1615
Filed: May 15, 2001 : Examiner: L.Channavajjala
For: **COMPOSITIONS COMPRISING CYCLODEXTRINS**

TERMINAL DISCLAIMER

Mail Stop AF
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Petitioner, The Procter & Gamble Company, is the owner of the entire right, title and interest in the above-identified application U.S. Serial No. 09/855,337, as evidenced by the Global General Assignment, a copy of which was submitted to the USPTO during prosecution of this application in a terminal disclaimer filed on March 13, 2003.

Petitioner is the owner of the entire right, title and interest in U.S. Patent No. 6,878,695 by virtue of the assignment recorded on October 28, 2002, at Reel: 013201, Frame: 0299, as evidenced by the pertinent entry in the USPTO Assignment data base, a copy of which is attached hereto.

Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application Serial No. 09/855,337 which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §154 to §156 and §173, as shortened by any terminal disclaimer filed prior to the grant of U.S. Patent No. 6,878,695.

BEST AVAILABLE COPY

BEST AVAILABLE COPY

Petitioner hereby agrees that any patent so granted on the above-identified application Serial No. 09/855,337 shall be enforceable only for and during such period that it and the patent are commonly owned. This agreement runs with any patent granted on the above-identified application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the above-identified application Serial No. 09/855,337 that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §154 to §156 and §173 of the '695 patent, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The evidentiary documents for the assignments have been reviewed by the undersigned, and the undersigned certifies that to the best of his/her knowledge and belief, title is in the assignee to take this action. The undersigned is an attorney or agent of record and is empowered to act on behalf of the assignee.

The undersigned hereby declares that all statements made herein of his/her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

By: 

Brent M. Peebles
Registration No. 38,576
The Procter & Gamble Company
Ivorydale Technical Center
5299 Spring Grove Avenue
Cincinnati, Ohio 45217-1025
(513) 627-4597

Date: December 20, 2006